Clinical challenges associated with universal screening for lynch syndrome-Associated endometrial cancer

Amanda Bruegl, Kari L. Ring, Molly Daniels, Bryan M. Fellman, Diana L. Urbauer, Russell R. Broaddus

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Universal testing for Lynch syndrome is now a routine component of the diagnostic work-up of endometrial cancer patients. The purpose of this study was to identify prospectively the barriers to universal screening based on a tissue testing approach [microsatellite instability (MSI) analysis, IHC for DNA mismatch repair proteins, and MLH1 methylation analysis]. Endometrial carcinoma patients (n = 213) prospectively underwent microsatellite instability and IHC testing for expression of DNA mismatch repair (MMR) proteins. Patients with low (MSI-L) or high (MSI-H) levels of tumor MSI or immunohistochemical loss of MLH1 (and absent MLH1 methylation), MSH2, MSH6, or PMS2 were referred to a genetic counselor for consideration of germline testing. Six discordances (3.1% of tested cases) between IHC and MSI were identified. Half of these exhibited heterogeneous immunohistochemical loss of MLH1/PMS2 and were microsatellite stable (MSS). Of the remaining cases, one was MSS with immunohistochemical loss of MSH6, one was MSS with immunohistochemical loss of MLH1/PMS2 and absent MLH1 promoter methylation, and one was MSI-H with intact expression of DNA MMR proteins. Four patients had MSI-L tumors with intact immunohistochemical protein expression; the clinical significance of MSI-L in endometrial cancer is unclear. Eight patients did not have germline mutations despite tissue testing suggesting Lynch syndrome. Including cases with insufficient tissue for testing and patients declining tissue or germline testing, we encountered significant barriers to universal screening in 13.6% of screened patients (29/213) that preclude designation of a tumor as sporadic or hereditary.

Original languageEnglish (US)
Pages (from-to)108-115
Number of pages8
JournalCancer Prevention Research
Volume10
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

Hereditary Nonpolyposis Colorectal Neoplasms
Microsatellite Instability
Endometrial Neoplasms
DNA Mismatch Repair
Microsatellite Repeats
Methylation
Neoplasms
Proteins
Germ-Line Mutation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical challenges associated with universal screening for lynch syndrome-Associated endometrial cancer. / Bruegl, Amanda; Ring, Kari L.; Daniels, Molly; Fellman, Bryan M.; Urbauer, Diana L.; Broaddus, Russell R.

In: Cancer Prevention Research, Vol. 10, No. 2, 01.02.2017, p. 108-115.

Research output: Contribution to journalArticle

Bruegl, Amanda ; Ring, Kari L. ; Daniels, Molly ; Fellman, Bryan M. ; Urbauer, Diana L. ; Broaddus, Russell R. / Clinical challenges associated with universal screening for lynch syndrome-Associated endometrial cancer. In: Cancer Prevention Research. 2017 ; Vol. 10, No. 2. pp. 108-115.
@article{8bb8522701524ff6a430189be69936ce,
title = "Clinical challenges associated with universal screening for lynch syndrome-Associated endometrial cancer",
abstract = "Universal testing for Lynch syndrome is now a routine component of the diagnostic work-up of endometrial cancer patients. The purpose of this study was to identify prospectively the barriers to universal screening based on a tissue testing approach [microsatellite instability (MSI) analysis, IHC for DNA mismatch repair proteins, and MLH1 methylation analysis]. Endometrial carcinoma patients (n = 213) prospectively underwent microsatellite instability and IHC testing for expression of DNA mismatch repair (MMR) proteins. Patients with low (MSI-L) or high (MSI-H) levels of tumor MSI or immunohistochemical loss of MLH1 (and absent MLH1 methylation), MSH2, MSH6, or PMS2 were referred to a genetic counselor for consideration of germline testing. Six discordances (3.1{\%} of tested cases) between IHC and MSI were identified. Half of these exhibited heterogeneous immunohistochemical loss of MLH1/PMS2 and were microsatellite stable (MSS). Of the remaining cases, one was MSS with immunohistochemical loss of MSH6, one was MSS with immunohistochemical loss of MLH1/PMS2 and absent MLH1 promoter methylation, and one was MSI-H with intact expression of DNA MMR proteins. Four patients had MSI-L tumors with intact immunohistochemical protein expression; the clinical significance of MSI-L in endometrial cancer is unclear. Eight patients did not have germline mutations despite tissue testing suggesting Lynch syndrome. Including cases with insufficient tissue for testing and patients declining tissue or germline testing, we encountered significant barriers to universal screening in 13.6{\%} of screened patients (29/213) that preclude designation of a tumor as sporadic or hereditary.",
author = "Amanda Bruegl and Ring, {Kari L.} and Molly Daniels and Fellman, {Bryan M.} and Urbauer, {Diana L.} and Broaddus, {Russell R.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1158/1940-6207.CAPR-16-0219",
language = "English (US)",
volume = "10",
pages = "108--115",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Clinical challenges associated with universal screening for lynch syndrome-Associated endometrial cancer

AU - Bruegl, Amanda

AU - Ring, Kari L.

AU - Daniels, Molly

AU - Fellman, Bryan M.

AU - Urbauer, Diana L.

AU - Broaddus, Russell R.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Universal testing for Lynch syndrome is now a routine component of the diagnostic work-up of endometrial cancer patients. The purpose of this study was to identify prospectively the barriers to universal screening based on a tissue testing approach [microsatellite instability (MSI) analysis, IHC for DNA mismatch repair proteins, and MLH1 methylation analysis]. Endometrial carcinoma patients (n = 213) prospectively underwent microsatellite instability and IHC testing for expression of DNA mismatch repair (MMR) proteins. Patients with low (MSI-L) or high (MSI-H) levels of tumor MSI or immunohistochemical loss of MLH1 (and absent MLH1 methylation), MSH2, MSH6, or PMS2 were referred to a genetic counselor for consideration of germline testing. Six discordances (3.1% of tested cases) between IHC and MSI were identified. Half of these exhibited heterogeneous immunohistochemical loss of MLH1/PMS2 and were microsatellite stable (MSS). Of the remaining cases, one was MSS with immunohistochemical loss of MSH6, one was MSS with immunohistochemical loss of MLH1/PMS2 and absent MLH1 promoter methylation, and one was MSI-H with intact expression of DNA MMR proteins. Four patients had MSI-L tumors with intact immunohistochemical protein expression; the clinical significance of MSI-L in endometrial cancer is unclear. Eight patients did not have germline mutations despite tissue testing suggesting Lynch syndrome. Including cases with insufficient tissue for testing and patients declining tissue or germline testing, we encountered significant barriers to universal screening in 13.6% of screened patients (29/213) that preclude designation of a tumor as sporadic or hereditary.

AB - Universal testing for Lynch syndrome is now a routine component of the diagnostic work-up of endometrial cancer patients. The purpose of this study was to identify prospectively the barriers to universal screening based on a tissue testing approach [microsatellite instability (MSI) analysis, IHC for DNA mismatch repair proteins, and MLH1 methylation analysis]. Endometrial carcinoma patients (n = 213) prospectively underwent microsatellite instability and IHC testing for expression of DNA mismatch repair (MMR) proteins. Patients with low (MSI-L) or high (MSI-H) levels of tumor MSI or immunohistochemical loss of MLH1 (and absent MLH1 methylation), MSH2, MSH6, or PMS2 were referred to a genetic counselor for consideration of germline testing. Six discordances (3.1% of tested cases) between IHC and MSI were identified. Half of these exhibited heterogeneous immunohistochemical loss of MLH1/PMS2 and were microsatellite stable (MSS). Of the remaining cases, one was MSS with immunohistochemical loss of MSH6, one was MSS with immunohistochemical loss of MLH1/PMS2 and absent MLH1 promoter methylation, and one was MSI-H with intact expression of DNA MMR proteins. Four patients had MSI-L tumors with intact immunohistochemical protein expression; the clinical significance of MSI-L in endometrial cancer is unclear. Eight patients did not have germline mutations despite tissue testing suggesting Lynch syndrome. Including cases with insufficient tissue for testing and patients declining tissue or germline testing, we encountered significant barriers to universal screening in 13.6% of screened patients (29/213) that preclude designation of a tumor as sporadic or hereditary.

UR - http://www.scopus.com/inward/record.url?scp=85011990216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011990216&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-16-0219

DO - 10.1158/1940-6207.CAPR-16-0219

M3 - Article

VL - 10

SP - 108

EP - 115

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 2

ER -